Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
Key Highlights
- ➤Iovance will report third-quarter 2026 results and corporate updates November 5, 2026.
- ➤Amtagvi is FDA-approved for previously treated advanced melanoma in three global markets.
- ➤Amtagvi is available at nearly 100 authorized treatment centers.
- ➤Iovance’s centralized U.S. manufacturing is scaled to serve thousands of patients annually.
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates.
To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/j9pwh6ke. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year.
Get started
Create a free account to read the full story.